News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
13-Oct-2010 - KINAXO Biotechnologies GmbH announced that Bristol-Myers Squibb Company has chosen KINAXO to support several of its drug discovery programs. Under the terms of the agreement, KINAXO will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing ...
10-Sep-2010 - Bristol-Myers Squibb Company and ZymoGenetics, Inc. have announced the signing of a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb for USD 9.75 per share in cash. The transaction has been unanimously approved by the Boards of Directors of both ...
04-Sep-2009 - DxS has entered into a collaboration agreement with Bristol-Myers Squibb Company and ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to further develop a K-RAS companion diagnostic for ERBITUX® (cetuximab) in the United States and Canada. If approved by the U.S. Food and ...
31-Aug-2009 - Bristol-Myers Squibb Company announced that the initial tender offer, through its wholly owned subsidiary, Puma Acquisition Corporation, for all outstanding shares of common stock of Medarex, Inc. expired at midnight (New York City time) on August 26, 2009, and was not extended. The depositary ...
24-Jul-2009 - Bristol-Myers Squibb Company and Medarex, Inc. announced that the companies have signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The transaction, with an aggregate purchase price of approximately $2.4 billion, ...
14-Nov-2007 - Aureus Pharma announced that Bristol-Myers Squibb Company has renewed its license to Aureus' AurSCOPE GPCR, and has also licensed Aureus' AurSCOPE Kinase and Ion Channel Knowledge databases. According to the company, Aureus Pharma's target-family-based AurSCOPE knowledge databases contain ...
Co-development and co-commercialization of Erbitux in metastatic colorectal cancer upon health authority approval
19-Oct-2007 - Merck KGaA announced that it has established an agreement with ImClone Systems Incorporated and Bristol-Myers Squibb Company for the co-development and co-commercialization of Erbitux® (cetuximab) in Japan if approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Under ...
10-Jul-2007 - Medivir announced that Bristol-Myers Squibb has terminated the development of the preclinical HIV compound MIV-170. The compound did not meet the profile desired by Bristol-Myers Squibb. MIV-170 belongs to the group of polymerase inhibitors that Medivir already discontinued the development of and ...
14-Jun-2007 - Albany Molecular Research, Inc. announced that a compound being developed under its license and research agreement with Bristol-Myers Squibb Company will proceed into preclinical development, triggering a $1.5 million payment to AMRI. This marks the first milestone in the ongoing research ...
20-Dec-2006 - Exelixis, Inc. and Bristol-Myers Squibb Company announced a worldwide collaboration to discover, develop and commercialize novel targeted therapies for the treatment of cancer. Under the collaboration, which will become effective upon antitrust clearance, Exelixis will deploy its drug discovery ...
© 1997-2024 LUMITOS AG, All rights reserved